{"context":{"query":">>mondo>>gwas","source_dataset":"mondo","target_dataset":"gwas"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0008315,73,MONDO:0008315,110,1]["},"schema":"id|disease_trait|mapped_gene|chr_id|p_value","mappings":[{"input":"MONDO:0008315","source":"MONDO:0008315|prostate cancer","targets":["GCST90042670_1|Illnesses of father: Prostate cancer (UKB data field 20107_13)|PCAT1, CASC19|8|8.000000e-25","GCST90042670_2|Illnesses of father: Prostate cancer (UKB data field 20107_13)|HOXB13|17|3.000000e-09","GCST90043894_1|ICD10 C61: Malignant neoplasm of prostate|PCAT1, CASC19|8|3.000000e-34","GCST90043894_2|ICD10 C61: Malignant neoplasm of prostate|HOXB13|17|2.000000e-29","GCST90096811_1|Conversion from active surveillance to active treatment in prostate cancer|LINC01897 - HMGN1P30|18|3.000000e-08","GCST90096811_10|Conversion from active surveillance to active treatment in prostate cancer|F7 - F10|13|5.000000e-08","GCST90096811_11|Conversion from active surveillance to active treatment in prostate cancer|SMIM5, RECQL5|17|6.000000e-06","GCST90096811_12|Conversion from active surveillance to active treatment in prostate cancer|RFNG|17|7.000000e-08","GCST90096811_13|Conversion from active surveillance to active treatment in prostate cancer|HCN2|19|4.000000e-08","GCST90096811_14|Conversion from active surveillance to active treatment in prostate cancer|MYADM-AS1, MYADM|19|7.000000e-08","GCST90096811_2|Conversion from active surveillance to active treatment in prostate cancer|HMGN1P31 - CDH20|18|4.000000e-08","GCST90096811_3|Conversion from active surveillance to active treatment in prostate cancer|IL12RB1|19|5.000000e-07","GCST90096811_4|Conversion from active surveillance to active treatment in prostate cancer|RBBP8NL - GATA5|20|3.000000e-07","GCST90096811_5|Conversion from active surveillance to active treatment in prostate cancer|LINC01101 - Y_RNA|2|5.000000e-10","GCST90096811_6|Conversion from active surveillance to active treatment in prostate cancer|LINC02018, ENPP7P2|3|2.000000e-08","GCST90096811_7|Conversion from active surveillance to active treatment in prostate cancer|MROH1|8|9.000000e-08","GCST90096811_8|Conversion from active surveillance to active treatment in prostate cancer|VAV2|9|4.000000e-06","GCST90096811_9|Conversion from active surveillance to active treatment in prostate cancer|EBF3|10|8.000000e-10","GCST90101894_1|Prostate cancer|MTNR1A|4|1.000000e-06","GCST90101894_2|Prostate cancer|CASC15|6|7.000000e-07","GCST90101894_3|Prostate cancer|WDR88|19|3.000000e-06","GCST90296486_1|High-risk prostate cancer|MCCC1|3|1.000000e-05","GCST90399469_1|Prostate cancer|LINC00506 - MIR4795|3|2.000000e-09","GCST90399469_10|Prostate cancer|MSMB - RPL23AP61|10|4.000000e-18","GCST90399469_11|Prostate cancer|RNU6-66P - RNU4-10P|13|3.000000e-08","GCST90399469_12|Prostate cancer|CORO2B|15|5.000000e-11","GCST90399469_13|Prostate cancer|HNF1B|17|8.000000e-10","GCST90399469_14|Prostate cancer|PDLIM5|4|1.000000e-07","GCST90399469_15|Prostate cancer|PCAT1|8|2.000000e-07","GCST90399469_16|Prostate cancer|EEFSEC|3|9.000000e-07","GCST90399469_17|Prostate cancer|WDR11 - RPL19P16|10|1.000000e-06","GCST90399469_18|Prostate cancer|LINC00506|3|3.000000e-06","GCST90399469_2|Prostate cancer|CTD-2194D22.4|5|9.000000e-10","GCST90399469_3|Prostate cancer|SINHCAFP3 - NKX3-1|8|5.000000e-19","GCST90399469_4|Prostate cancer|CASC8 - CASC11|8|9.000000e-43","GCST90399469_5|Prostate cancer|PCAT1, CASC19, PRNCR1|8|4.000000e-42","GCST90399469_6|Prostate cancer|PCAT1, CASC19|8|9.000000e-21","GCST90399469_7|Prostate cancer|CASC8 - CASC11|8|2.000000e-08","GCST90399469_8|Prostate cancer|CASC8|8|3.000000e-08","GCST90399469_9|Prostate cancer|PCAT1|8|4.000000e-08","GCST90428117_1|Prostate cancer|LINC02208, LINC02147|5|3.000000e-06","GCST90428117_10|Prostate cancer|EML4|2|2.000000e-06","GCST90428117_100|Prostate cancer|PCBP3|21|8.000000e-07","GCST90428117_101|Prostate cancer|SSBL6P - LINC01326|3|8.000000e-07","GCST90428117_102|Prostate cancer|TROAP-AS1|12|1.000000e-09","GCST90428117_103|Prostate cancer|GGCX|2|1.000000e-09","GCST90428117_104|Prostate cancer|ZNF652-AS1|17|2.000000e-09","GCST90428117_105|Prostate cancer|VAMP8|2|2.000000e-09","GCST90428117_106|Prostate cancer|||3.000000e-09","GCST90428117_107|Prostate cancer|SIDT1|3|3.000000e-09","GCST90428117_108|Prostate cancer|SLC22A2|6|3.000000e-09","GCST90428117_109|Prostate cancer|PCAT1|8|8.000000e-09","GCST90428117_11|Prostate cancer|MTCH2P2 - PLEKHG7|12|2.000000e-06","GCST90428117_110|Prostate cancer|VPS53|17|1.000000e-08","GCST90428117_111|Prostate cancer|SIDT1|3|1.000000e-08","GCST90428117_112|Prostate cancer|THADA|2|1.000000e-08","GCST90428117_113|Prostate cancer|PDLIM5|4|1.000000e-08","GCST90428117_114|Prostate cancer|RN7SL478P - LMTK2|7|2.000000e-08","GCST90428117_115|Prostate cancer|JAZF1|7|3.000000e-08","GCST90428117_116|Prostate cancer|CTBP2|10|3.000000e-08","GCST90428117_117|Prostate cancer|TROAP-AS1|12|3.000000e-08","GCST90428117_118|Prostate cancer|CNTNAP4|16|3.000000e-08","GCST90428117_119|Prostate cancer|STN1 - SLK|10|4.000000e-08","GCST90428117_12|Prostate cancer|CHD3|17|2.000000e-06","GCST90428117_120|Prostate cancer|VPS53|17|5.000000e-08","GCST90428117_121|Prostate cancer|THADA|2|5.000000e-08","GCST90428117_122|Prostate cancer|TERT - MIR4457|5|5.000000e-08","GCST90428117_123|Prostate cancer|FAM162B - GPRC6A|6|6.000000e-08","GCST90428117_124|Prostate cancer|ATF7IP2|16|7.000000e-08","GCST90428117_125|Prostate cancer|PDLIM5|4|9.000000e-08","GCST90428117_126|Prostate cancer|LINC00934|12|1.000000e-07","GCST90428117_127|Prostate cancer|HLA-C - USP8P1|6|8.000000e-07","GCST90428117_128|Prostate cancer|RNU1-29P - KCND2|7|8.000000e-07","GCST90428117_129|Prostate cancer|CNTNAP2|7|8.000000e-07","GCST90428117_13|Prostate cancer|HIBADH|7|2.000000e-06","GCST90428117_130|Prostate cancer|TAX1BP1, JAZF1|7|8.000000e-07","GCST90428117_131|Prostate cancer|PGBD5 - LINC01737|1|8.000000e-07","GCST90428117_132|Prostate cancer|SNORD65B - GOLGA7|8|9.000000e-07","GCST90428117_133|Prostate cancer|RPL23AP54 - RN7SKP159|8|9.000000e-07","GCST90428117_134|Prostate cancer|POU1F1|3|9.000000e-07","GCST90428117_135|Prostate cancer|NRXN3|14|9.000000e-07","GCST90428117_136|Prostate cancer|||9.000000e-07","GCST90428117_137|Prostate cancer|||9.000000e-07","GCST90428117_138|Prostate cancer|MUC22 - HCG22|6|9.000000e-07","GCST90428117_139|Prostate cancer|AK8|9|9.000000e-07","GCST90428117_14|Prostate cancer|TET2-AS1|4|2.000000e-06","GCST90428117_140|Prostate cancer|PPIAP68 - INO80D|2|1.000000e-06","GCST90428117_141|Prostate cancer|SNHG32|6|1.000000e-06","GCST90428117_142|Prostate cancer|FRMD4A|10|1.000000e-06","GCST90428117_143|Prostate cancer|||1.000000e-06","GCST90428117_144|Prostate cancer|PCBP3|21|1.000000e-06","GCST90428117_145|Prostate cancer|TAX1BP1-AS1|7|1.000000e-06","GCST90428117_146|Prostate cancer|MTA3|2|1.000000e-06","GCST90428117_147|Prostate cancer|EPHB1 - SDHBP1|3|1.000000e-06","GCST90428117_148|Prostate cancer|ATF7IP2|16|1.000000e-06","GCST90428117_149|Prostate cancer|ANKIB1|7|1.000000e-06","GCST90428117_15|Prostate cancer|RPS23P10 - FCGR3A|1|2.000000e-06","GCST90428117_150|Prostate cancer|RSPO2|8|1.000000e-06","GCST90428117_151|Prostate cancer|WDPCP|2|1.000000e-06","GCST90428117_152|Prostate cancer|TERT|5|5.000000e-13"]}]}